Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-HEB
2024-516241-39-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of propranolol in von Hippel–Lindau disease (VHL) and Haemangioblastoma (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Treatment response at 24 months. Planned start Oct 2024; status: authorised.
02
Drugs
propranolol
03
Conditions
von Hippel–Lindau disease (VHL)Haemangioblastoma
Beyond the preview
Go deeper on 2024-516241-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516241-39-00.